Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States.

ABSTRACT: It is not clear if all Americans have benefitted equally from the availability of chimeric antigen receptor T-cell (CART) therapy. We aimed to evaluate if demographic differences existed among adult patients who received CART therapy and to assess predictors of CART treatment outcomes. Records of patients ≥18 years who received CART therapy for non-Hodgkin's lymphoma, acute lymphoblastic leukemia, and multiple myeloma in 2018 were evaluated in the National Inpatient Sample. Acute complications and inhospital mortality were compared between two groups of CART recipients: Whites and non-Whites. Logistic regression analysis was used to evaluate the association between sociodemographic factors and inhospital mortality. Of 1275 CART recipients that met inclusion criteria, there were 40.4% of fe

SUBMITTER: Emole J 

PROVIDER: S-EPMC9741965 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature